



Accelero Participates in TRAIN-HEART Marie Curie Program Discovering RNA Therapeutics for Heart Failure

Berlin, 04 June 2019

Accelero is pleased to announce that the company participates as a partner organization in the Marie Curie TRAIN-HEART consortium funded by the European Commission.

TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who can expand the scientific horizons and accelerate future development of RNA-based therapeutics for the treatment of ischemic heart failure.

The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems. More information can be found on the consortium website www.train-heart.eu.

Accelero Bioanalytics GmbH is a GLP certified contract research service provider for regulatory drug development and maintains genetic engineering (bio)safety level 2 laboratories in compliance with ICH GCP regulations.

Accelero will invite all 15 fellows from 12 institutions located in 6 European countries to a “GLP Summer Seminar 2019” to provide training in the principles of Good Laboratory Practice (GLP).

Furthermore, Accelero will host two fellows from the University of Porto for a secondment period of two months. These fellows will be trained ‘on the job’ by working in the GLP compliant bioanalytical R&D facility and learn about the development of bioanalytical test methods for the quantification of RNA therapeutics.



This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.

© TRAIN HEART 2019

accelerō bioanalytics



Press Release

For additional information on our services, please feel free to use our contact form, or send us an email to [service\(at\)accelero-bioanalytics.com](mailto:service(at)accelero-bioanalytics.com). The Accelerero team will be happy to assist you.

Accelerero Bioanalytics GmbH
Center for Biotechnology and Environment
Volmerstrasse 9A
12489 Berlin
GERMANY

Primary Contact:
Christian Lange, Founder & Managing Director
Telephone +49 30 610 910 300

qPCR
Biodistribution
ELISA
EliSpot / FluoroSpot
Flow cytometry
Multiplex immunoassays
Multiplex miRNA assays
Cell culture
Microbiology
GLP trainings & seminars

Follow us on



Read binding-assay.com for blog and case studies.

accelero bioanalytics

REGULATORY BIOANALYTICS FOR YOUR ATMP DEVELOPMENT

ACCELERO SERVICE

- PCR - Biodistribution - Shedding
- RT-PCR - Gene Expression
- EliSpot - Triple FluoroSpot - Virus Plaque Assays
- ELISA - Flow Cytometry - Immunogenicity Testing
- Multiplex Immunoassays & Multiplex miRNA Assays
- PBMC Isolation - Cell Culture - Microbiology
- Clinical Kit Building & Logistics
- GLP Trainings - Audits - Seminars

ACCELERO EXPERIENCE

- Living Biotherapeutics
- Oncolytic Viruses
- Adeno-Associated Vectors (AAV)
- Human Mesenchymal Cells
- Microbial Cell-Based Therapeutics

GLP certified - Biosafety Level 3** - Genetic Engineering Safety Level 2
www.accelero-bioanalytics.com www.binding-assay.com (Blog)

GLP AND GCP CONTRACT RESEARCH